Small extracellular vesicle-loaded bevacizumab reduces the frequency of intravitreal injection required for diabetic retinopathy
Rattachement africain : in, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Diabetic retinopathy (DR) is associated with retinal neovascularization, hard exudates, inflammation, oxidative stress and cell death, leading to vision loss.Anti-vascular endothelial growth factor (Anti-VEGF) therapy through repeated intravitreal injections is an established treatment for reducing VEGF levels in the retina for inhibiting neovascularization and leakage of hard exudates to prevent vision loss.Although anti-VEGF therapy has several clinical benefits, its monthly injection potentially causes devastating ocular complications, including trauma, intraocular hemorrhage, retinal detachment, endophthalmitis, etc. Methods: As mesenchymal stem cells (MSCs) and MSC-derived extracellular vesicles (MSC-EVs) demonstrated safety in clinical studies, we have tested the efficacy of MSC-derived small EVs (MSC-sEVs) loaded anti-VEGF drug bevacizumab in a rat model of DR.Results: The study identified a clinically significant finding that sEV loaded with bevacizumab reduces the frequency of intravitreal injection required for treating diabetic retinopathy.The sustained effect is observed from the reduced levels of VEGF, exudates and leukostasis for more than two months following intravitreal injection of sEV loaded with bevacizumab, while bevacizumab alone could maintain reduced levels for about one month.Furthermore, retinal cell death was consistently lower in this period than only bevacizumab.Conclusion: This study provided significant evidence for the prolonged benefits of sEVs as a drug delivery system.Also, EV-mediated drug delivery systems could be considered for clinical application of retinal diseases as they maintain vitreous clarity in the light path due to their composition being similar to cells.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Small extracellular vesicle-loaded bevacizumab reduces the frequency of intravitreal injection required for diabetic retinopathy
- Date Crossref
- 01/01/2023
- Éditeur
- Ivyspring International Publisher
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Manipal Academy of Higher Education pays non établi dans la noticeUniversité ou école supérieure
-
Kasturba Medical College Centre for Molecular Neurosciences pays non établi dans la noticeUniversité ou école supérieure
-
University of Missouri pays non établi dans la noticeUniversité ou école supérieure
-
Texas A&M Health Science Center pays non établi dans la noticeUniversité ou école supérieure
-
Texas A&M University pays non établi dans la noticeUniversité ou école supérieure
-
Centre for Biotherapeutics Research pays non établi dans la noticeInstitution
-
Manipal College of Pharmaceutical Sciences Department of Pharmaceutical Biotechnology pays non établi dans la noticeUniversité ou école supérieure
-
School of Medicine Department of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
College of Medicine Institute for Regenerative Medicine pays non établi dans la noticeUniversité ou école supérieure
Manipal Academy of Higher Education, Centre for Molecular Neurosciences — Kasturba Medical College et University of Missouri, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.